Salt CompositionAmoxicillin 250mg + Sulbactam 250mg
WHO GMP
Certified
15 Days Easy
Returns
Long Expiry
(>8 Months)
WHO GMP
Certified
15 Days Easy
Returns
Long Expiry
(>8 Months)
Used In
Bacterial infections
Customers also bought
More About Amphy IBL 250/250mg Dry Syrup 30ml
Benefits
In Bacterial infections Amphy IBL Dry Syrup contains two different medicines that work together to kill the bacteria that cause infections. Amoxycillin belongs to a group of medicines called penicillins that work by stopping the growth of bacteria. Sulbactam is a beta-lactamase inhibitor that reduces resistance and enhances the activity of Amoxycillin against bacteria. Amphy IBL Dry Syrup can be used to treat many different bacterial infections such as ear, sinus, throat, lung, urinary tract, skin, teeth, joints, and bones. This medicine usually makes you feel better within a few days, but you should continue taking it as prescribed even when you feel better to make sure that all bacteria are killed and do not become resistant.
Side Effects
The majority of side effects typically do not necessitate medical intervention. and disappear as your body adjusts to the medicine. Doctor consultation is advised if they persist or if you're worried about them.
How to use
Follow your doctor's guidance regarding the dose and duration of this medication. Check the label for directions before use. Dissolve the powder in sterile water. Shake well and use. Amphy IBL Dry Syrup is to be taken with food.
How it works
Amphy IBL Dry Syrup is a combination of two medicines: Amoxycillin and Sulbactam. Amoxycillin is an antibiotic. It works by preventing the formation of the bacterial protective covering which is essential for the survival of bacteria. Sulbactam is a beta-lactamase inhibitor which reduces resistance and enhances the activity of Amoxycillin against bacteria.
Safe: No harmful side effects are associated with consuming alcohol alongside Amphy IBL Dry Syrup
Safe when prescribed by an expert: Amphy IBL Dry Syrup is generally considered safe to use during pregnancy. Animal studies have shown low or no adverse effects to the developing baby; however, there are limited human studies.
Safe when prescribed by an expert: Amphy IBL Dry Syrup is safe to use during breastfeeding. Human studies suggest that the drug does not pass into the breastmilk in a significant amount and is not harmful to the baby.
Not Safe: Amphy IBL Dry Syrup may cause side effects which could affect your ability to drive. Amphy IBL Dry Syrup can have side effects and the symptoms (such as allergic reactions, dizziness and convulsions) may make you unfit to drive.
Caution Advised: Amphy IBL Dry Syrup should be used with caution in patients with kidney disease. Dose adjustment of Amphy IBL Dry Syrup may be needed. Doctor consultation is advised. Use of this medicine is not recommended in patients with severe kidney disease.
Caution Advised: Amphy IBL Dry Syrup should be used with caution in patients with liver disease. Dose adjustment of Amphy IBL Dry Syrup may be needed. Doctor consultation is advised. Regular monitoring of liver function tests is recommended while you are taking this medicine
What if I forget to take it?
If a dose of Amphy IBL Dry Syrup is missed, take it promptly. However, if your next dose is approaching, skip the missed dose and resume your regular schedule. Avoid doubling the dose.
Manufacturer Address
B-222, Layak Ram Complex, Badarpur, New Delhi- 110044
References
Amoxicillin. Bristol, Tennessee: Dr. Reddys Laboratories Tennessee LLC.; 1974 (04 Feb. 2019)
Amoxycillin. Research Triangle Park, NC: GlaxoSmithKline; Oct. 2006 (10 Apr. 2019)
ScienceDirect. Sulbactam (09 Apr. 2019)
Disclaimer
PlatinumRx is dedicated to delivering dependable and trustworthy information to empower our customers. However, the information presented here is solely for general informational purposes and should not be utilized for diagnosing, preventing, or treating health issues. It is not intended to establish a doctor-patient relationship or serve as a substitute for professional medical advice.
